Invex Therapeutics (ASX:IXC) Ending Cash Position: A$4.60 Mil (As of Dec. 2025)


ASX:IXC Invex Therapeutics Ltd ASX:IXC
38 GF Score
Price A$0.11
! 1 Warning Sign
View Full Analysis

What is Invex Therapeutics Ending Cash Position?

Invex Therapeutics ASX:IXC 38 Ending Cash Position is A$4.60 Mil as of Dec. 2025. GuruFocus rates ASX:IXC with a GF Score™ of 38/100. The stock has 1 warning sign investors should review.

Invex Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 was A$4.60 Mil.

Invex Therapeutics's quarterly Ending Cash Position declined from Dec. 2024 (A$5.81 Mil) to Jun. 2025 (A$5.38 Mil) and declined from Jun. 2025 (A$5.38 Mil) to Dec. 2025 (A$4.60 Mil).

Invex Therapeutics's annual Ending Cash Position declined from Jun. 2023 (A$22.47 Mil) to Jun. 2024 (A$6.03 Mil) and declined from Jun. 2024 (A$6.03 Mil) to Jun. 2025 (A$5.38 Mil).

Invex Therapeutics Ending Cash Position Related Terms

Invex Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Ending Cash Position Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial 32.72 29.34 22.47 6.03 5.38

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.15 6.03 5.81 5.38 4.60
ASX:IXC
38GF Score
Invex Therapeutics Ltd ASX:IXC
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invex Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Invex Therapeutics's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=6.025+-0.65
=5.38

Invex Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=5.375+-0.78
=4.60

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$4.60 Mil mean?
Invex Therapeutics (ASX:IXC) has a Ending Cash Position of A$4.60 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' Ending Cash Position too high?
Invex Therapeutics' current Ending Cash Position is A$4.60 Mil. Overall, Invex Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' Ending Cash Position compare to VRTX and REGN?
Invex Therapeutics' Ending Cash Position of A$4.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current Ending Cash Position is A$4.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Ending Cash Position of A$4.60 Mil. The current Ending Cash Position is A$4.60 Mil. Invex Therapeutics' overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Ending Cash Position is A$4.60 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
38GF Score

Get the complete analysis for ASX:IXC

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price